A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial-Reference-Cited by-同舟云学术

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

Published:2004-07-15 Issue:14_suppl Volume:22 Page:7022-7022
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Shepherd F. A.¹,Pereira J.¹,Ciuleanu T. E.¹,Tan E. H.¹,Hirsh V.¹,Thongprasert S.¹,Bezjak A.¹,Tu D.¹,Santabárbara P.¹,Seymour L.¹

Affiliation:

1. NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2004.22.90140.7022

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis;JAMA Ophthalmology;2024-02-01

2. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present);Pharmaceuticals;2023-04-03

3. Untargeted Lipidomics of Non-Small Cell Lung Carcinoma Demonstrates Differentially Abundant Lipid Classes in Cancer vs. Non-Cancer Tissue;Metabolites;2021-10-28

4. Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer);Principles of Clinical Cancer Genetics;2010

5. Treatment of non-small cell lung cancer patients with performance status2 (PS2);Lung Cancer;2009-01